# Shaker R. Dakhil

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shaker-r-dakhil/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,972 |
| Field | Cancer Treatment and Pharmacology |
| h-index | 81 |
| i10-index | 237 |
| Last Known Institution | Cancer Center of Kansas |
| OpenAlex ID | https://openalex.org/A5064449830 |
| ORCID iD | https://orcid.org/0000-0002-6261-5882 |
| Works | 442 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/rituximab-chop-versus-chop-alone-or-with-maintenance-rituximab-in-older-patients/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial](https://scholariq.org/papers/venlafaxine-in-management-of-hot-flashes-in-survivors-of-breast-cancer-a/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)

## Researcher topics

- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Cancer Center of Kansas](https://scholariq.org/institutions/cancer-center-of-kansas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.